Monocyte chemoattractant protein 1 as a potential biomarker for immune checkpoint inhibitor‐associated neurotoxicity

BACKGROUND: Oncological patients can benefit substantially from treatment with immune checkpoint inhibitors (ICI). However, there is a growing awareness of immune‐related adverse events (irAE). Especially ICI‐mediated neurological adverse events (nAE(+)), are tough to diagnose and biomarkers to iden...

Descripción completa

Detalles Bibliográficos
Autores principales: Möhn, Nora, Mahjoub, Susann, Duzzi, Laura, Narten, Emily, Grote‐Levi, Lea, Körner, Gudrun, Seeliger, Tabea, Beutel, Gernot, Bollmann, Benjamin‐Alexander, Wirth, Thomas, Huss, André, Tumani, Hayrettin, Grimmelmann, Imke, Gutzmer, Ralf, Ivanyi, Philipp, Skripuletz, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166892/
https://www.ncbi.nlm.nih.gov/pubmed/36794673
http://dx.doi.org/10.1002/cam4.5695

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166892/
https://www.ncbi.nlm.nih.gov/pubmed/36794673
http://dx.doi.org/10.1002/cam4.5695

Ejemplares similares